IPP Bureau
Glenmark launches Whatsapp based chatbot-‘Hello Skin’ for patients suffering from fungal infections
By IPP Bureau - May 24, 2022
'Hello Skin' has been developed in collaboration with the IADVL (Indian Association of Dermatologists, Venereologists and Leprologists)
Alembic Pharmaceuticals receives USFDA final approval for Pirfenidone tablets
By IPP Bureau - May 24, 2022
The tablets have an estimated market size of US $ 548 million for twelve months ending December 2021 according to IQVIA
Apollo Hospitals Navi Mumbai doctors perform critical procedure to save 14-month-old baby girl
By IPP Bureau - May 24, 2022
Successfully removed peanut from the child’s left lung through bronchoscopy
HNZ Lifesciences unveils its new brand Amio Wellness
By IPP Bureau - May 24, 2022
The key categories include intimate wellness, skincare & hair care
AbbVie showcases its leadership in Rheumatology research with new data across multiple inflammatory joint diseases
By IPP Bureau - May 24, 2022
The hybrid congress will take place from 1-4 June in Copenhagen, as well as virtually
Lonza to expand inhalation capabilities at Tampa site
By IPP Bureau - May 24, 2022
Lonza to expand inhalation services by adding capabilities at its Tampa (US) site as part of its continued focus on providing bioavailability enhancement series for global customers
NHA announces revamped ABHA mobile application
By IPP Bureau - May 24, 2022
The revamped Ayushman Bharat Health Account (ABHA) mobile application offers added functionalities and a new User Interface (UI)
Launch of joint research to collect a year’s worth of lifestyle data through wearable tracking device
By IPP Bureau - May 23, 2022
Objective tracking data combined with cohort data to drive medicine of the future
Vaxzevria approved in the EU as third dose booster against Covid-19
By IPP Bureau - May 23, 2022
Approval follows CHMP recommendation for use in patients previously vaccinated with Vaxzevria or an EU-approved mRNA Covid-19 vaccine
CHMP recommends European Commission approval of Rinvoq
By IPP Bureau - May 23, 2022
Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients
Crosscope and Farcast Biosciences join efforts to reshape the precision oncology landscape
By IPP Bureau - May 23, 2022
The two companies will work together for the Prospective Evaluation of OrionAI – a revolutionary AI-based Diagnostic Assistant for Histological Examination of a variety of solid tumours beginning with Head and Neck Squamous Cell Carcinoma (HNSCC) Cancer
50% of the world's population expected to be myopic by 2050
By IPP Bureau - May 23, 2022
Researchers have found out that myopia often leads to an abnormal increase in axial length. When the axial length grows to more than 25mm, especially with age, problems like cataracts or glaucoma can appear
Dapagliflozin met primary endpoint in DELIVER Phase III trial
By IPP Bureau - May 23, 2022
Results from the DELIVER and DAPA-HF Phase III trials demonstrate Dapagliflozin’ efficacy in heart failure regardless of ejection fraction
New study finds that Masimo PVi may be useful in helping ER doctors determine the severity of asthma attacks
By IPP Bureau - May 23, 2022
Acute asthma attack is a common cause of admission to emergency departments (EDs) among children, and triage by severity is important for determining appropriate clinical treatment
Merck KGaA to expand its membrane and filtration manufacturing facility in Ireland
By IPP Bureau - May 23, 2022
The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland
